These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22349053)

  • 1. Modeling dispersion of dry powders for inhalation. The concepts of total fines, cohesive energy and interaction parameters.
    Thalberg K; Berg E; Fransson M
    Int J Pharm; 2012 May; 427(2):224-33. PubMed ID: 22349053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
    Thalberg K; Åslund S; Skogevall M; Andersson P
    Int J Pharm; 2016 May; 504(1-2):27-38. PubMed ID: 26965200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
    Cordts E; Steckel H
    Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers.
    Jetmalani K; Young PM; Smith T; Stewart P; Traini D
    Drug Dev Ind Pharm; 2012 Dec; 38(12):1504-11. PubMed ID: 22335558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing".
    Young PM; Cocconi D; Colombo P; Bettini R; Price R; Steele DF; Tobyn MJ
    J Pharm Pharmacol; 2002 Oct; 54(10):1339-44. PubMed ID: 12396294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
    Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
    AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy. 1: Budesonide and lactose.
    Marek SR; Donovan MJ; Smyth HD
    Eur J Pharm Biopharm; 2011 May; 78(1):97-106. PubMed ID: 21182942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
    Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
    Int J Pharm; 2018 Jan; 535(1-2):59-67. PubMed ID: 29100914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
    Zeng XM; Pandhal KH; Martin GP
    Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
    Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
    Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entrainment of lactose inhalation powders: a study using laser diffraction.
    Watling CP; Elliott JA; Cameron RE
    Eur J Pharm Sci; 2010 Jul; 40(4):352-8. PubMed ID: 20417708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance.
    Faulhammer E; Wahl V; Zellnitz S; Khinast JG; Paudel A
    Int J Pharm; 2015 Aug; 491(1-2):231-42. PubMed ID: 26136200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.